Skip to main content

Predicted Tauopathies, Including clinical trials at UCSF
1 in progress, 0 open to new patients

  • Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

    Sorry, in progress, not accepting new patients

    The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology, corticobasal degeneration syndrome [CBS] or progressive supranuclear palsy [PSP]). The secondary objectives of this study are to obtain preliminary data on short term changes (at 12 weeks) in a variety of clinical, functional and biomarker measurements from baseline, including cerebrospinal fluid (CSF) tau levels, eye movements, and brain MRI measurements.

    San Francisco, California